US one-cent coin for comparison Seroquel XR 150 mg tablet box<unk>  is primarily used to treat schizophrenia or bipolar disorder.<unk>  targets both positive and negative symptoms of schizophrenia. Schizophrenia A 2013 Cochrane review compared<unk>  to typical antipsychotics: +<unk>  compared to typical antipsychotics for schizophrenia Summary<unk>  may not differ from typical antipsychotics in the treatment of positive symptoms, general psychopathology, and negative symptoms. However, it causes fewer adverse effects in terms of abnormal ECG, extrapyramidal effects, abnormal prolactin levels and weight gain. Outcome Findings in words Findings in numbers Quality of evidence Global state No clinical significant response There is no clear difference between people given<unk>  and those receiving typical antipsychotic drugs. These findings are based on data of moderate quality. RR 0.96 (0.75 to 1.23) Moderate Mental state Average positive symptom score (PANSS) On average, people receiving<unk>  scored higher (worse) than people treated with typical antipsychotic drugs. There was, however, no clear difference between the groups. This finding is based on data of moderate quality. MD 0.02 higher (0.39 lower to 0.43 higher)* Moderate Average negative symptom score (PANSS) On average, people receiving<unk>  scored lower (better) than people treated with typical antipsychotic drugs. This finding is based on data of moderate quality. MD 0.82 lower (1.59 to 0.04 lower)* Moderate Cognitive function Average score On average, people receiving<unk>  scored higher (better) than people treated with typical antipsychotic drugs. There was no clear difference between the groups. This finding is based on data of very limited quality. MD 1.55 higher (0.62 lower to 3.72 higher)* Very low Leaving the study early For any reason<unk>  is not clearly more acceptable than typical antipsychotic drugs. These findings are based on data of moderate quality. RR 0.91 (0.81 to 1.01) Moderate Adverse effects Extrapyramidal effects<unk>  may reduce the chance of experiencing these movement disorders. This finding is based on data of moderate quality. RR 0.17 (0.09 to 0.32) Moderate Prolactin levelAverage level (ng/mL) On average, people receiving<unk>  scored lower (better) than people treated with typical antipsychotic drugs. There was a clear difference between the groups. This finding is based on data of moderate quality. MD 16.20 lower (23.34 to 9.07 lower)* Moderate *The meaning of these findings for day-to-day care is not clear In a 2013 comparison of 15 antipsychotics in effectiveness in treating schizophrenia,<unk>  demonstrated standard effectiveness. It was 13–16% more effective than ziprasidone, chlorpromazine, and asenapine and approximately as effective as haloperidol and aripiprazole. There is tentative evidence of the benefit of<unk>  versus placebo in schizophrenia; however, definitive conclusions are not possible due to the high rate of attrition in trials (greater than 50%) and the lack of data on economic outcomes, social functioning, or quality of life. It is debatable whether, as a class, typical or atypical antipsychotics are more effective. Both have equal drop-out and symptom relapse rates when typicals are used at low to moderate dosages. While<unk>  has lower rates of extrapyramidal side effects, there is greater sleepiness and rates of dry mouth. A Cochrane review comparing<unk>  to other atypical antipsychotic agents tentatively concluded that it may be less efficacious than olanzapine and risperidone; produce fewer movement related side effects than paliperidone, aripiprazole, ziprasidone, risperidone and olanzapine; and produce weight gain similar to risperidone, clozapine and aripiprazole. They concluded that it produces suicide attempt, suicide; death; QTc prolongation, low blood pressure; tachycardia; sedation; gynaecomastia; galactorrhoea, menstrual irregularity and white blood cell count at a rate similar to first generation antipsychotics. Bipolar disorder In those with bipolar disorder,<unk>  is used to treat depressive episodes; acute manic episodes associated with bipolar I disorder (as either monotherapy or adjunct therapy to lithium; valproate or lamotrigine); acute mixed episodes; and maintenance treatment of bipolar I disorder (as adjunct therapy to lithium or divalproex). Major depressive disorder<unk>  is effective when used by itself and when used along with other medications in major depressive disorder (MDD). However, sedation is often an undesirable side effect. In the United States, the United Kingdom and Australia (while not subsidised by the Australian Pharmaceutical Benefits Scheme for treatment of MDD),<unk>  is licensed for use as an add-on treatment in MDD. Alzheimer's disease<unk>  does not decrease agitation among people with Alzheimer's.<unk>  worsens intellectual functioning in the elderly with dementia and therefore is not recommended. Others The use of low doses of<unk>  for insomnia, while common, is not recommended; there is little evidence of benefit and concerns regarding adverse effects. Doses of<unk>  used for insomnia have ranged from 12.5 to 800 mg, with low doses of 25 to 200 mg being the most typical. It is sometimes used off-label, often as an augmentation agent, to treat conditions such as Tourette syndrome, musical hallucinations and anxiety disorders.<unk>  and clozapine are the most widely used medications for the treatment of Parkinson's disease psychosis due to their very low extrapyramidal side-effect liability. Owing to the risks associated with clozapine (e.g. agranulocytosis, diabetes mellitus, etc.), clinicians often attempt treatment with<unk>  first, although the evidence to support<unk> 's use for this indication is significantly weaker than that of clozapine.
Quetiapine
Sertraline
Mirtazapine
Fluparoxan
Asenapine
Aripiprazole
Citalopram
Loxapine